Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

Pfizer

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: DMARDs or Biologics

Study type: Observational

Funder types: Industry

Identifiers

NCT00929357

0881X1-4617

Details and patient eligibility

About

This study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs) or Biologics and have two existing, consecutive radiographs (x-ray images) of hand and feet taken as part of routine treatment monitoring within a time interval of 12 to 36 months.

Enrollment: 156 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Secure diagnosis of rheumatoid arthritis
• Older than 18 years
• Two consecutive plain radiographs of the hands and feet with a time interval of 12 to 36 months are available. The radiographs are recorded 2003 or later and are in accordance with a defined X-ray protocol.

Exclusion criteria

• Patients who receive Anakinra, Rituximab or Abatacept

Trial design

156 participants in 2 patient groups

1

Description:

DMARDs

Treatment:

Drug: DMARDs or Biologics

2

Description:

Biologics

Treatment:

Drug: DMARDs or Biologics